NEW YORK, June 1, 2026, 13:04 EDT
Neogen Corp shares edged lower in Monday afternoon Nasdaq trading, lagging a firmer technology-led tape as investors kept the food- and animal-safety testing company in a holding pattern before its next operating update. The stock traded at $8.94, down about 0.4%, after moving between $8.75 and $9.15; its market value was about $1.94 billion, market data showed.
The move was small. The message was not. Neogen is still being judged less on the day’s market mood than on whether it can turn Food Safety growth, cost cuts and a planned portfolio exit into steadier earnings.
Wall Street’s broader backdrop was mixed, with the Nasdaq Composite higher while the Dow fell and the S&P 500 was flat earlier in the session, as technology gains offset oil-driven geopolitical worries. That gave Neogen little help either way; this was more of a company-specific wait-and-see trade than a sector chase.
Neogen develops, makes and sells products used in food and animal safety. Its Food Safety unit includes diagnostic test kits and culture media used by food producers to detect pathogens, allergens, drug residues and sanitation problems; its Animal Safety unit sells veterinary, diagnostic, biosecurity and genomics-related products.
The last big set of numbers remains the April 9 fiscal third-quarter report. Revenue fell 4.4% to $211.2 million, Food Safety sales rose 2.6%, Animal Safety sales dropped 20.1%, and Neogen lifted fiscal 2026 revenue guidance to $857 million to $860 million while keeping adjusted EBITDA near $175 million. Adjusted EBITDA is a non-GAAP profit measure, meaning it excludes interest, taxes, depreciation, amortization and some other items; investors use it as a rough read on operating earnings power. CEO Mike Nassif said the company had made “significant progress” on its transformation, but also pointed to “third-party, supply-based setbacks” in Animal Safety. Neogen Investors
One operating marker came later in April. In an SEC filing, Neogen said it had completed multiple operational qualifications for certain Petrifilm single kit units and was moving to performance qualifications as part of validation work tied to investor tours of its Lansing, Michigan manufacturing facility. Petrifilm is a key food-safety testing platform, so the timing and quality of that manufacturing shift matter for margins and customer service.
Portfolio cleanup is the other leg of the story. Neogen agreed in March to sell its global genomics business to Zoetis for $160 million, subject to customary adjustments, with net proceeds expected to be used mainly for debt reduction. The unit generated about $90 million in fiscal 2025 sales. Nassif said the deal would help “accelerate de-leveraging and improve profitability.” Neogen Investors
There has also been product news, though not enough to move the stock sharply on its own. Neogen said on April 23 that its Listeria Right Now rapid environmental monitoring test received AOAC Performance Tested Methods certification, a third-party validation that a test performs as claimed. The company said the test can deliver results in about two hours without an enrichment step, and Chief Scientific Officer Dr. Jeremy Yarwood said “rapid and reliable detection of Listeria is critical.” Neogen Investors
In adjacent animal-health and diagnostics-linked shares, the tape was not uniform. Zoetis rose 0.5%, IDEXX Laboratories added 0.5%, and Thermo Fisher Scientific slipped 0.2%, leaving Neogen without a clear peer-group push in either direction.
But the downside case is still plain. Neogen has flagged risks tied to the continuing integration of the former 3M food-safety business, the performance of transition manufacturing partners, competition, research and development, and remediation of internal-control weaknesses. It has also disclosed shareholder litigation tied to alleged statements around the 2022 3M Food Safety transaction, which the company says it intends to defend vigorously.
For now, the shares are stuck in proof mode. A clean genomics sale, steadier Animal Safety supply and a smooth Petrifilm transition would make the guidance hike easier to own. Another stumble would leave investors staring again at a single-digit stock and asking how long the reset still has to run.
